Articles On Medadvisor (ASX:MDR)
Title | Source | Codes | Date |
---|---|---|---|
Closing Bell: ASX drops to three-month low, while CHESS system outage halts settlements
ASX hits three-month low as Fed dampens rate cut hopes ASX CHESS system is down Mesoblast shares reverse some of yesterday’s 50pc gain It’s been a rough week for Aussie shares, with the ASX 200 slumping to a three-month low on Friday. T... |
Stockhead | MDR | 5 days ago |
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns
The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX Paradigm Biopharmaceuticals rose 151% in Novembe... |
Stockhead | MDR | 3 weeks ago |
Scott Power: S&P/ASX 200 Health Care Index falls but which stocks are up on positive news?
ASX health stocks fall 1.3% in past five days, while broader market is marginally up 0.7% Neuren soars on sale of priority review voucher and $50 million share buyback Neurizon releases positive preclinical results on lead drug candidate... |
Stockhead | MDR | 1 month ago |
Closing Bell: Tech leads and goldies hit hard; Variscan jumps 50pc as Spanish zinc drilling begins
ASX up, Xero leads gains Miners hit as iron ore drops, Variscan jumps 50pc Asian stocks down, Bitcoin hits US$93k before retreating Aussie shares climbed higher on Thursday, powered by a rally in tech companies and the big banks. At the... |
Stockhead | MDR | 1 month ago |
October Health Winners: Uscom, Respiri lead sluggish sector, but ‘time in the market, not timing, is key’
ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th... |
Stockhead | MDR | 1 month ago |
ASX October Winners: The 50 best stocks in weaker month for markets
The S&P/ASX 200 fell 1.3% in October with small cap companies outperforming S&P Dow Jones Indices said financials led the gains in October and is up 30% YTD Ovanti rose 525% in October after appointment of former Zip US CFO Simon K... |
Stockhead | MDR | 1 month ago |
Closing Bell: Macquarie drags down bank stocks; Ironbark Zinc soars as Zelenski takes the chair
ASX opens November lower, led by financial sector sell-off Macquarie Group fell after profit decline Ironbark Zinc jumps 75% on new leadership The ASX kicked off November with a thud, sliding about 0.5%. This follows a tough session o... |
Stockhead | MDR | 1 month ago |
Scott Power: Which company dropped 30pc on its latest quarterly result?
ASX health stocks fall 2.15% in past five days, while broader market down 1.42% MedAdvisor drops 30% on latest quarterly result as MicroX and Mach 7 also fall Micro X reports a ‘ho-hum’ results, while AGMs so far remain rather uneventful ... |
Stockhead | MDR | 1 month ago |
Closing Bell: ASX dips as AGL stalls; Talga skyrockets after Sweden approves graphite mine
ASX slips amid earnings updates and company meetings AGL drops over 6pc after downgrade, while Origin Energy rises Talga surges after Sweden approves graphite mine The ASX slipped by 0.22% after being dragged by a flurry of company... |
Stockhead | MDR | 1 month ago |
September
Health Winners: EZZ and Althea lead upbeat sector sparked by Fed rate cut
Healthcare stocks are doing relatively well globally in 2024 The sector could see more recovery as Fed cuts rates How ASX biotechs performed in the month of September The S&P 500 Health Care Index, a key world benchmark for health... |
Stockhead | MDR | 2 months ago |
MedAdvisor Solutions Launches Pharmacy Advisory Group to Empower and Expand the Role of the Pharmacist
This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Industry leaders collaborate to bring innovative approaches to evolving pharmacy... |
FNArena | MDR | 3 months ago |
August Health Winners: LTR Pharma, Control Bionics lead sector at the ‘cusp of an extraordinary era’
ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment The ASX Healthcare Index (AS... |
Stockhead | MDR | 3 months ago |
Closing Bell: ASX up 0.22pc after slow start; iron ore miners, REA weigh on market
The ASX ended higher after a slow start Energy stocks leading while telcos and miners lagged Asian stocks mostly declined amid ongoing economic weakness After a sluggish start, the ASX ended Monday higher by 0.22% as September trading... |
Stockhead | MDR | 3 months ago |
ASX Health Stocks: Clinuvel, MedAdvisor rally after hitting high notes on profits
Clinuvel’s shares jump after reporting a $35.6 million profit for FY24 The company hits its eighth consecutive profitable year MedAdvisor turns a profit for the first time A couple of health stocks announced their FY24 earnings this mor... |
Stockhead | MDR | 3 months ago |
Market Highlights: Nvidia slumps despite crushing forecasts; and 5 ASX small caps to watch today
Nvidia’s stock dropped despite strong earnings and future guidance SuperMicro shares fell over 19pc due to a delay in filing annual report Telegram CEO Pavel Durov faces serious charges in France The ASX is expected to fall when the mar... |
Stockhead | MDR | 3 months ago |
Digital prescription: ASX stocks transforming healthcare sector
A cooperative research centre believes there is an opportunity to transform Australia’s healthcare sector through digital innovations Alcidion helps health organisations harnesses the power of technology to empower digitally enabled care B... |
Stockhead | MDR | 3 months ago |
ScoPo’s Powerplays: ASX health stocks rise as Pro Medicus again hit the ball out of the park”
ASX health stocks rise 0.8% past five days as broader market lifts 3.7% Morgans says ProMedicus ‘produced yet another record result’ with net profit of $82.8m in FY24 CSL falls on FY24 results but Morgans still bullish on ASX’s largest h... |
Stockhead | MDR | 4 months ago |
ScoPo’s Powerplays: ASX health stocks fall in stormy week but regain ground on Friday
ASX health stocks fall 0.37% over past five days in line with broader markets Cardiac company Imricor’s VISABL-AFL trial for US FDA starts in US LBT Innovations has secured a major deal with big pharma AstraZeneca Healthcare and life sci... |
Stockhead | MDR | 4 months ago |
July Health Winners: Oncosil, Zelira lead as ASX biotechs power through another strong month
S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July The S&P/ASX 200 Health Care index [XHJ]... |
Stockhead | MDR | 4 months ago |
Check Up: Europe delivers blow to Alzheimer’s research; and recent ASX health stock winners
The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month In a major blow for... |
Stockhead | MDR | 4 months ago |
Up 127% in 2024, why this ASX healthcare stock is surging again this month
It's been a decent start to both the month of July and the 2025 financial year for ASX shares so far. Since the end of FY24, the All Ordinaries Index (ASX: XAO) has risen by a tentative 0.25%. But let's talk about one ASX healthcare stock t... |
Motley Fool | MDR | 5 months ago |
ScoPo’s Powerplays: ASX health stocks hit resistance and fall in first week of FY25
ASX health stocks fall 0.19% in past five days as broader markets lift 0.79% Morgans says capital raises remain a theme for 2024 among healthcare stocks Pharmaceutical distributor EBOS increases stake in MedAdvisor to 9.8% Healthcare and... |
Stockhead | MDR | 5 months ago |
ASX Health June Winners: Actinogen and Optiscan led a sector in good shape
The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase... |
Stockhead | MDR | 5 months ago |
ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year
S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month The S&P/ASX 200 Health Care [XHJ] closed flattish for the month o... |
Stockhead | MDR | 6 months ago |
Check Up: Alzheimer’s is ‘preventable’, so here’s what you must do; and recent ASX biotech winners
Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month The phrase ‘you are what you eat’ was coined almost a c... |
Stockhead | MDR | 7 months ago |
Closing Bell: Webjet to split, BHP’s deadline dilemma, and Charger Metals up 70pc on lithium find
Tesltra slumps, iron ore miners gain BHP faces a deadline today to decide on its bid for Anglo America Webjet reveals plans to split its travel divisions, boosting its share price today The ASX 200 closed flattish on Wednesday, as big l... |
Stockhead | MDR | 7 months ago |
MedAdvisor Solutions forecasts continued growth for FY25 after stellar year
MedAdvisor Solutions (ASX: MDR) is forecasting further strong growth over the next 12 months after achieving robust recent performances in sales and revenue. The Melbourne-headquartered patient engagement solution provider reported strong m... |
SmallCaps | MDR | 7 months ago |
ASX Health Stocks: Health app firm MedAdvisor guides the market to record year and maiden profit
MedAdvisor guides the market to maiden profit MedAdvisor (ASX:MDR) jumped +15% this morning after providing guidance for the full year ending this June. Based on the strong start to Q4 FY24 and anticipated activity levels over the remainder... |
Stockhead | MDR | 7 months ago |
ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different
ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month The S&P/ASX 200 Health Care [XHJ] had a soft month in April... |
Stockhead | MDR | 7 months ago |
Buy Coles and these ASX dividend stocks
If you're on the look at for some ASX dividend stocks to buy for your income portfolio, then you may want to check out the three listed below. Here's what you need to know about these income options: Coles Group Ltd (ASX: COL) Analysts at... |
Motley Fool | MDR | 7 months ago |
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners
There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month Scientists have made a significant b... |
Stockhead | MDR | 8 months ago |
Here are the top 10 ASX 200 shares today
The S&P/ASX 200 Index (ASX: XJO) enjoyed another positive session today, as the recovery from last week's slump continues. A confident session saw the ASX 200 add a decent 0.4... |
Motley Fool | MDR | 8 months ago |
Market Close: ASX drives uphill on continued recovery
The ASX200 closed .4 of a per cent up with IT and Health Care the locomotives of a sluggish steam energy labouring under the weight of Energy and Industrials. IT and Health Care were up 1.73 and 1.22 per cent respectively whilst Energy a... |
themarketonline.com.au | MDR | 8 months ago |
Will the Reserve Bank wait for the US Fed to cut interest rates first?
While the US economy is seen as a leading indicator for the world, the US Fed is unlikely to be the first major central bank to start cutting interest rates, says AMP deputy chief economist Diana Mousina. Mousina points out that the US... |
Motley Fool | MDR | 8 months ago |
Healthco Healthcare, Medadvisor, Ramsay Health Care, and Tamboran shares are rising
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is pushing higher again. At the time of writing, the benchmark index is up 0.4% to 7,681.2 points. Four ASX shares that are rising more than most today are listed below. Here's why... |
Motley Fool | MDR | 8 months ago |
Wesfarmers shares baulk on fresh acquisition gossip
The Wesfarmers Ltd (ASX: WES) share price is treading water today on fresh acquisition rumours. Shares in the diverse retailing conglomerate are down 0.4% to $65.33. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) is up 0.4%. After a... |
Motley Fool | MDR | 8 months ago |
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr... |
Stockhead | MDR | 9 months ago |
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | MDR | 9 months ago |
MedAdvisor invests $1.9m in UK pharmacy app for 7.4pc share
MedAdvisor will pay £1 million (A$1.9 million) to UK pharmacy market app provider Charac Charac will see MedAdvisor pick up a 7.4 per cent shareholding MedAdvisor’s Rick Ratliff will become an NED on Charac’s board MedAdvisor wi... |
themarketherald.com.au | MDR | 1 year ago |
TMH Market Close: ASX200 slumps 0.76pc as real estate drags, IT edges higher
So much for a small rise on the market today. Instead, the ASX200 closed down about three quarters (.76) per cent. Real estate stocks proved the biggest drag, down just over one and a quarter of a per cent, while IT was the only sector t... |
themarketherald.com.au | MDR | 1 year ago |
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks China’s President Xi is expected... |
Stockhead | MDR | 1 year ago |
ASX Health Stocks: Amplia’s pancreatic cancer trial gets boost; Emyria’s MDMA therapy is one step closer
Amplia reports positive data from pancreatic cancer trial Emyria was given endorsement by ethical committee for its TGA application MedAdvisor’s Q1 sales were up 27pc Amplia reports promising data from pancreatic cancer trial Amplia The... |
Stockhead | MDR | 1 year ago |
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff
News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks Goldman Sachs analysts said they will make no... |
Stockhead | MDR | 1 year ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | MDR | 1 year ago |
Closing Bell: Local markets shed 0.6pc as we brace for tonight’s US Fed call
The ASX 200 benchmark falls 0.6% as we brace for news from The Fed Sector losses led by Resources, while Consumers make gains Small caps led by Alderan, and BNPL Sezzle returns Local markets made it a hat trick of losses, with the re... |
Stockhead | MDR | 1 year ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | MDR | 1 year ago |
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August August was all about earnings, and des... |
Stockhead | MDR | 1 year ago |
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | MDR | 1 year ago |
Market Highlights: US tech stocks rally, dividends at all-time high, and 5 ASX small caps to watch today
ASX is set to rise for a third consecutive day Tech stocks in the US rallied overnight after a soft jobs market report Dividends rose in Q2 in Australia and around the world The ASX is set to open higher for a third consecutive day afte... |
Stockhead | MDR | 1 year ago |
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month Steve Jobs used to say that the most... |
Stockhead | MDR | 1 year ago |